SEARCH

SEARCH BY CITATION

References

  • 1
    UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837853.
  • 2
    American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 2003; 26 (Suppl. 1): S28S32.
  • 3
    American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27 (Suppl. 1): S15S35.
  • 4
    American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management-2002 update. Endocr Pract 2002; 8 (Suppl. 1): 4083.
  • 5
    The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968983.
  • 6
    Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405412.
  • 7
    American College of Endocrinology Consensus Statement on Guidelines for Glycaemic Control. Endo Pract 2002; 8 (Suppl. 1): 111.
  • 8
    American Association of Clinical Endocrinologists (AACE) website. Diabetes Guidelines. http://www.aace. com/clin/guidelines/diabetes_2002.pdf .
  • 9
    Selvin E, Marinopoulos S, Berkenblit G et al. Meta- analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421431.
  • 10
    Qiao Q, Tuomilehto J, Borch-Johnsen K. Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia 2003; 46 (Suppl. 1): M17M21.
  • 11
    DECODE Study Group the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397405.
  • 12
    Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 15771583.
  • 13
    Marre M. Before oral agents fail: the case for starting insulin early. Int J Obes 2002; 26 (Suppl. 3): S25S30.
  • 14
    International Diabetes Federation, Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Retrieved September 14, 2005 from http://www.idf.org/home/index.cfm?unode=B7462CCB-3A4C-472C-80E4-710074D74AD3.
  • 15
    Weyer C, Heinemann L, Heise T. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid acting insulin analog in stable mixture. Diabetes, 1997; 20: 16121614.
  • 16
    Mcsorley PT, Bell PM, Jacobsen LV, Kristensen A, Lindholm A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002; 24: 530539.
  • 17
    Hermansen K, Colombo M, Storgaard H, Østergaard A, Kølendorf K, Madsbad S. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002; 25: 883888.
  • 18
    Declaration of Helsinki. Recommendations guiding medical physicians in biomedical research involving human subjects. JAMA 1997; 277: 925926.
  • 19
    Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care 2003; 26: 881885.
  • 20
    Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes. A comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260265.
  • 21
    Malone JK, Kerr LE, Campaigne BN, Sachson RA, Holcombe JH for the Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004; 26: 20342044.
  • 22
    Riddle MC, Rosenstock J, Gerich J. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 30803086.